Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Bucknelly21on Jul 13, 2021 11:09am
156 Views
Post# 33535696

RE:RE:RE:Will THTX backtrack from these statements??

RE:RE:RE:Will THTX backtrack from these statements??
jfm1330 wrote: Wow! Now I learned that the management of the company is likely dishonest. But you still think that the stock of a company likely lying on important financial stuff is undervalued. You are hard to follow... But I finally got it, the stock price is so undervalued because the market cannot trust a management that likely lies on important matters. So if they lied there, why not on oncology potential, why not on NASH real approval potential?

So oncology has zero value, the management likely lied on sales growth, they are blowing up their credibility with investors. I now understand why some are pushing for a CYDY pumping approach. In fact, what you are asking the management is this: don't just lie a bit, if you are to lie, lie the whole way. Pump the stock price out of nothing so we can sell.

All that is not serious. The level of bitterness here is out of control.


SPCEO1 wrote: They already backtracked last quarter on the sales growth statement. I forget the exact wording but it was something that suggested tepid growth short term and better growth long term. My belief is that the 20-25% projection was made just to support the OO. They knew it was nonsense at the time. So, yes management likely lied to investors about that and then quickly retracted it when Q1's ugly results were released. You may remember me fuming about them blowing up their credibility with investors again.
longterm56 wrote: Although TXTH has been very tight-lipped (wow, that's an understatement), there are two statements directly from Paul that he has not yet retracted or modified (from what I recall): 
  • NASH trial to begin in 3rd quarter
  • 20-25% Q/Q growth of revenues from Egrifta & Trogarzo. 
We'll see if he comments on or retracts either of these on Thursday. 

   -LT

 

 


jfm very much I respect your contribution I have learned so much, but you are wrong on this, no one is asking for lies. The market and investment community looks to a company for confidence in what they are doing and working on. If you don't say anything other that what is public knowledge and a bare minimum you create zero excitement resulting in no one paying attention beside the select few who are willing to dig into it on their own. It's exactly why companies trade on multiples. Not sure why you don't understand that

<< Previous
Bullboard Posts
Next >>